163 related articles for article (PubMed ID: 1356458)
21. The prognostic value of the tumour markers CA 195 and CEA in patients with adenocarcinoma of the pancreas.
Taylor OM; Cooper EH; Benson EA; McMahon MJ
Eur J Surg Oncol; 1992 Oct; 18(5):508-13. PubMed ID: 1426303
[TBL] [Abstract][Full Text] [Related]
22. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
23. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
24. [Diagnostic value of aspiration cytology with ERCP].
Ortí E; Canelles P; Tomé A; Calvo MA; Martorell M; Medina E; Benages A
Rev Esp Enferm Dig; 1993 Sep; 84(3):173-7. PubMed ID: 8217383
[TBL] [Abstract][Full Text] [Related]
25. [Value of serum CA 19-9 determination in the diagnosis of pancreatic carcinoma].
Pei DP
Zhonghua Wai Ke Za Zhi; 1990 Oct; 28(10):625-7, 638-9. PubMed ID: 2086060
[TBL] [Abstract][Full Text] [Related]
26. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
Safi F; Roscher R; Beger HG
Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
[TBL] [Abstract][Full Text] [Related]
27. Immunological diagnosis of pancreatic cancer by assaying carcinoembryonic antigen (CEA) in pure pancreatic juice.
Nishida K; Yoshikawa T; Kondo M; Thiele HG
Hepatogastroenterology; 1980 Dec; 27(6):488-94. PubMed ID: 7203382
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis of pancreatic cancer by cytology and measurement of oncogene and tumor markers in pure pancreatic juice aspirated by endoscopy.
Nakaizumi A; Uehara H; Takenaka A; Uedo N; Sakai N; Yano H; Ohigashi H; Ishikawa O; Ishiguro S; Sugano K; Tatsuta M
Hepatogastroenterology; 1999; 46(25):31-7. PubMed ID: 10228761
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy.
Yamaguchi T; Shirai Y; Ishihara T; Sudo K; Nakagawa A; Ito H; Miyazaki M; Nomura F; Saisho H
Cancer; 2005 Dec; 104(12):2830-6. PubMed ID: 16287152
[TBL] [Abstract][Full Text] [Related]
30. [Assay of serum elastase 1 in adenocarcinoma of the pancreas: diagnostic value, compared and combined study with serum CEA and CA 19-9].
Charneau J; Douay O; Daver A; Boyer J
Gastroenterol Clin Biol; 1988; 12(6-7):548-52. PubMed ID: 3166429
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
Ohkura H; Sakawaki T
Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
[TBL] [Abstract][Full Text] [Related]
32. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
Röthlin M; Metzger U; Joller H; Largiadèr F
Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
34. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
Robles-Diáz G; Aceves G; Galván E
Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
[TBL] [Abstract][Full Text] [Related]
35. [Developing a hospital-based high risk scoring model and screening strategy for pancreatic cancer].
Deng RX; Lu XH; Wang L; Li H; Qian JM; Yang AM; Zhong SX; Guo XZ; Zhou L; Wu X; Yang XO; Jiang WJ
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2038-42. PubMed ID: 16313796
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of CA 50 and CA 19-9 tumor markers in benign and malignant diseases of the upper gastrointestinal tract].
Heptner G; Domschke S; Schneider MU; Siegfried W; Domschke W
Dtsch Med Wochenschr; 1986 Mar; 111(10):374-8. PubMed ID: 2419074
[TBL] [Abstract][Full Text] [Related]
38. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease.
Matsubayashi H; Canto M; Sato N; Klein A; Abe T; Yamashita K; Yeo CJ; Kalloo A; Hruban R; Goggins M
Cancer Res; 2006 Jan; 66(2):1208-17. PubMed ID: 16424060
[TBL] [Abstract][Full Text] [Related]
39. [Tumor markers in the diagnosis of tumors in the subhepatic area].
Dufek V; Petrtýl J; Klener P; Chmel J
Vnitr Lek; 1994 Jun; 40(6):350-3. PubMed ID: 8073643
[TBL] [Abstract][Full Text] [Related]
40. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology.
Rosty C; Christa L; Kuzdzal S; Baldwin WM; Zahurak ML; Carnot F; Chan DW; Canto M; Lillemoe KD; Cameron JL; Yeo CJ; Hruban RH; Goggins M
Cancer Res; 2002 Mar; 62(6):1868-75. PubMed ID: 11912167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
